{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:04:34Z","timestamp":1780491874216,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIA","award":["AG016570"],"award-info":[{"award-number":["AG016570"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 AG010129"],"award-info":[{"award-number":["P30 AG010129"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K01 AG030514"],"award-info":[{"award-number":["K01 AG030514"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.neurobiolaging.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T23:03:14Z","timestamp":1334271794000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative"],"prefix":"10.1016","volume":"34","author":[{"given":"Joshua D.","family":"Grill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ringman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana G.","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Kohannim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/alzrt2","article-title":"Alzheimer's disease therapeutic research: the path forward","volume":"1","author":"Aisen","year":"2009","journal-title":"Alzheimers Res. Ther"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s12603-010-0065-2","article-title":"Pre-dementia Alzheimer's trials: overview","volume":"14","author":"Aisen","year":"2010","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0b013e318207b1b9","article-title":"Report of the task force on designing clinical trials in early (predementia)","volume":"76","author":"Aisen","year":"2011","journal-title":"Adv. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","article-title":"Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans","volume":"6","author":"Aisen","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archneur.63.5.693","article-title":"Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps","volume":"63","author":"Apostolova","year":"2006","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.neurobiolaging.2008.08.008","article-title":"Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal","volume":"31","author":"Apostolova","year":"2010","journal-title":"Neurobiol. Aging"},{"issue":"Suppl 3","key":"10.1016\/j.neurobiolaging.2012.03.006_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JAD-2011-0062","article-title":"Power calculations for clinical trials in Alzheimer's disease","volume":"26","author":"Ard","year":"2011","journal-title":"J. Alzheimers Dis"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neuroimage.2010.02.064","article-title":"Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative","volume":"51","author":"Chen","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.neurobiolaging.2010.05.001","article-title":"Ranking the clinical and pathological correlates of ventricular expansion mapped in 804 Alzheimer's disease, MCI, and normal elderly subjects","volume":"31","author":"Chou","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.neuroimage.2007.11.047","article-title":"Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer's disease","volume":"40","author":"Chou","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0013164401614002","article-title":"A primer on the understanding, use, and calculation of confidence intervals that are based on central and noncentral distributions","volume":"61","author":"Cumming","year":"2001","journal-title":"Educ. Psychol. Meas"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.biopsych.2010.09.020","article-title":"What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?","volume":"68","author":"Cummings","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"Suppl 3","key":"10.1016\/j.neurobiolaging.2012.03.006_bib15","first-page":"S14","article-title":"Maintaining adherence and retention in dementia prevention trials","volume":"67","author":"DeKosky","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ana.22509","article-title":"Amyloid-beta associated volume loss occurs only in the presence of phospho-tau","volume":"70","author":"Desikan","year":"2011","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1212\/WNL.0b013e3182166e96","article-title":"Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults","volume":"76","author":"Dickerson","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jalz.2010.12.013","article-title":"Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials","volume":"7","author":"Donohue","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","article-title":"Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study","volume":"6","author":"Feldman","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archneur.57.3.339","article-title":"Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects","volume":"57","author":"Fox","year":"2000","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib24","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib25","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1212\/WNL.0b013e3182343314","article-title":"Predicting MCI outcome with clinically available MRI and CSF biomarkers","volume":"77","author":"Heister","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib26","doi-asserted-by":"crossref","first-page":"20954","DOI":"10.1073\/pnas.0906053106","article-title":"Subregional neuroanatomical change as a biomarker for Alzheimer's disease","volume":"106","author":"Holland","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.neuroimage.2009.07.011","article-title":"Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects","volume":"48","author":"Hua","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1212\/01.WNL.0000110315.26026.EF","article-title":"Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD","volume":"62","author":"Jack","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib29","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awq277","article-title":"Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease","volume":"133","author":"Jack","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1602\/neurorx.1.3.307","article-title":"FDA: evidentiary standards for drug development and approval","volume":"1","author":"Katz","year":"2004","journal-title":"Neuro.Rx"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.neurobiolaging.2010.04.022","article-title":"Boosting power for clinical trials using classifiers based on multiple biomarkers","volume":"31","author":"Kohannim","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0b013e3181e8e8b8","article-title":"Comparing predictors of conversion and decline in mild cognitive impairment","volume":"75","author":"Landau","year":"2010","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.neurobiolaging.2012.03.006_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002093-199601031-00009","article-title":"Observations and suggestions on antidementia drug development","volume":"10","author":"Leber","year":"1996","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib35","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.neuroimage.2010.03.018","article-title":"Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease","volume":"51","author":"Leung","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.neuroimage.2009.12.059","article-title":"Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection","volume":"50","author":"Leung","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/archneurol.2011.123","article-title":"Longitudinal Change of Biomarkers in Cognitive Decline","volume":"68","author":"Lo","year":"2011","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.neurobiolaging.2010.04.036","article-title":"Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment","volume":"31","author":"Lorenzi","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib39","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WAD.0b013e3181d1b814","article-title":"Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease","volume":"24","author":"McEvoy","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib42","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/hbm.20708","article-title":"Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls","volume":"30","author":"Morra","year":"2009","journal-title":"Hum. Brain Mapp"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuroimage.2008.07.003","article-title":"Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls","volume":"43","author":"Morra","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1109\/TMI.2009.2021941","article-title":"Comparison of AdaBoost and support vector machines for detecting Alzheimer's disease through automated hippocampal segmentation","volume":"29","author":"Morra","year":"2010","journal-title":"IEEE Trans. Med. Imaging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib45","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","article-title":"FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease","volume":"36","author":"Mosconi","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib48","first-page":"A9","article-title":"NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues","volume":"68","author":"Samson","year":"2010","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib49","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archneurol.2010.118","article-title":"Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease","volume":"67","author":"Okonkwo","year":"2011","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib51","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib52","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjopharm.2009.06.003","article-title":"Drug development for Alzheimer's disease: Where are we now and where are we headed?","volume":"7","author":"Sabbagh","year":"2009","journal-title":"Am. J. Geriatr. Pharmacother"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/WAD.0b013e3181f883b7","article-title":"Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease","volume":"25","author":"Sano","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2010.07.004","article-title":"Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials","volume":"6","author":"Schneider","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib56","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.neurobiolaging.2010.04.011","article-title":"Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment","volume":"31","author":"Schott","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ana.22315","article-title":"Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42","volume":"68","author":"Schott","year":"2010","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awp007","article-title":"MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers","volume":"132","author":"Schuff","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib60","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib61","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(08)61047-8","article-title":"Will anti-amyloid therapies work for Alzheimer's disease?","volume":"372","author":"St George-Hyslop","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib62","series-title":"Psychological Appraisal of Children With Cerebral Deficits","author":"Taylor","year":"1959"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"issue":"Suppl","key":"10.1016\/j.neurobiolaging.2012.03.006_bib64","first-page":"S1","article-title":"A review of papers published since its inception","volume":"8","author":"Weiner","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2012.03.006_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458012001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458012001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:19:19Z","timestamp":1759317559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458012001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0197458012001984"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.03.006","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}